[Frankestin]

HCW Biologics has recently completed a $5 million follow-on offering, selling 671,140 units at $7.45 per unit, each consisting of one share and two five-year warrants. Armistice Capital appears to be the main investor, as evidenced by the progressive exercise of pre-funded warrants disclosed in late May, with 374,140 shares already issued and 139,000 still available.
Combined with the April offering, which raised about $2.5 million through the sale of shares and warrants, HCWB has now secured approximately $7.5 million in fresh capital. Add to that the recently recognized $7 million in licensing revenue from WY Biotech, and the company should now have at least $14.5 million in cash.
This strengthens their financial position not only to meet potential NASDAQ listing requirements (such as price and equity thresholds), but also to actively advance preclinical and clinical programs. Let’s not forget the previously disclosed $40 million equity line of credit — a powerful tool for the company’s financing flexibility, but potentially dilutive for existing shareholders depending on how and when it's used.
With stronger cash reserves, a focused pipeline targeting age-related diseases, and increasing chances of commercial partnerships, things might finally be heating up for HCWB, IMO.

[Frankestin]

Still waiting — When an agreement?

[Frankestin]

2025-05-19 785,43 - how it runs!

[Frankestin]

34 minutes ago 2025-05-19 11:34:45.789 90,000
1 hour ago 2025-05-19 10:32:40.342 100,000
At 2025-05-19 474.84
Waiting for some agreement not only to sell shares

[Frankestin]

US: HCWB Short Shares Availability 0
hold! Please don't have Weak Hands!

[Frankestin]

Start, Min, Max, Latest (Borrow Rates)
2025-05-16 439.00 439.00 439.00 439.00

[Frankestin]

On May 13, 2025, the Company received a compliance letter from the Nasdaq Panel to confirm that the Company has regained compliance with the bid price requirement in Listing Rule 5550(a)(2), the public float requirement in Listing Rule 5550(a)(4), and the market value of publicly held shares requirement in Listing Rule 5550(a)(5), as required by the Nasdaq Panel decision of April 8, 2025, as amended. The Company remains subject to the remaining terms of the Panel’s April 8, 2025, decision to provide an extension to the compliance period for other Listing Rules. The Company must be in compliance with all Listing Rules by June 16, 2025.

[Frankestin]

Borrow Fee
Date Start Min Max Latest
2025-05-15 130.42 130.42 368.35 368.35

[Frankestin]

Wong Hing C. (CEO and 10% owner): Purchased 92,500 shares at $26.00 each, for a total of $2,405,000.
Rebecca Byam (CFO): Purchased 8,462 shares at $26.00 each, for a total of $220,012.
Scott T. Garrett (Director): Purchased 5,385 shares at $26.00 each, for a total of $140,010.
Gary M. Winer (Director): Purchased 2,308 shares at $26.00 each, for a total of $60,008.
Rick S. Greene (Director): Purchased 962 shares at $26.00 each, for a total of $25,012.
Lee Flowers (SVP of Business Development): Purchased 962 shares at $26.00 each, for a total of $25,012.
Investors aren’t actually paying $26/share. They’re converting existing debt into equity at that “nominal” price — and getting compensated with warrants and shares of another company to make up the difference from the real value.
Wugen is a privately held company that has raised over $200 million in venture capital funding, backed by investors such as Aisling Capital .
Relationship with HCW Biologics
Wugen has acquired rights to certain molecules developed by HCW Biologics, generating revenue for HCW Biologics from the sale of licensed molecules.
Wugen Presents Positive Phase 2 Data for WU-CART-007

[Frankestin]

At the moment, there are no new equity issuances; they could be waiting to announce important updates.
It looks like all the offerings are closed, and the warrants too. Also the offering dated November 18, 2024, has been completed!: https://investors.hcwbiologics.com/static-files/2979764d-ee4f-45c3-8d19-99b6a924c32a#page4

[Frankestin]

for now they have made the warrant holders happy. Did they sell? in any case they have 15 million for 2.181.345.

Dr. Hing C. Wong, the Founder and CEO of the Company, commented, “HCW9206 is a promising revolutionary reagent to replace anti-CD3/anti-CD28/IL-2-based approaches to streamline and lower the costs of CAR-T manufacturing. Equally important, HCW9206 can improve the functional activities and persistence of CAR-Ts following adoptive transfer, a goal that has not been achieved for the last decade. Also, it provides us with an in-road opportunity to participate in the development of the highly promising, emergent “in-vivo CAR-T manufacturing technology”.

The GMP master cell bank of HCW9206 and its manufacturing process has been established, and its drug master file as an ex vivo reagent has also been filed with the US Food and Drug Administration. The Company is now seeking commercial partnerships for HCW9206 reagent sale and/or integration into CAR-T based manufacturing processes.

Our clinical development program is based on a few select lead product candidates which will be evaluated in Company-sponsored clinical trials in autoimmune disorders, solid tumors and quality-of-life conditions. We have a large portfolio of non-core programs and assets and, for these, we anticipate that clinical development will be conducted through licensing agreements and other business development transactions
HCWB has an experienced team led by Dr. Hing C. Wong, our Founder and CEO, who discovered and developed the
immunotherapeutic Anktiva® (also known as ALT-803, an IL-15 agonist receptor) through pivotal trials. This blockbuster immunotherapeutic treatment for cancer was sold to ImmunityBio, Inc. in 2017 in a S1.0 billion acquisition. Anktiva® was approved by the U.S. Food and Drug Administration ("FDA") for a bladder cancer indication in 2024.

[Frankestin]

https://investors.hcwbiologics.com/static-files/2cd0850c-f3a7-4166-9814-302ed2feb9ee

[Frankestin]

I'll add a little, I don't have much but if it drops I'll load it up!

[RAlbert]

Stock halted!!!

[Frankestin]

once we're over 20 we start dancing!

[Frankestin]

Form 4 - Statement of changes in beneficial ownership of securities May 09 2025
I see a nice BO here! Like Vertex buys everything and the others go to hell!

[Frankestin]

If it hits highs of $100 I wouldn't be surprised! But who's the fool selling at these prices!

[Frankestin]

HCW9206: A Hidden Gem in the CAR-T Ecosystem?
HCW Biologics (NASDAQ: HCWB) has just presented compelling data on its proprietary fusion protein, HCW9206, showing significant improvement in CAR-T production and functionality. The reagent enhances persistence and potency of CAR-Ts by promoting the generation of stem cell memory T cells (Tscm)—a long-sought goal in immunotherapy.
What makes HCW9206 unique?
Replaces conventional anti-CD3/CD28/IL-2 protocols
Improves viral transduction, cell expansion, and in vivo persistence
Enables generation of Tscm-like CAR-Ts with higher anti-tumor efficacy
Already GMP-ready with a Drug Master File filed at FDA
Available for commercial partnerships

Based on licensing precedents in the CAR-T space and the platform nature of the reagent, here’s a rough valuation range if the company successfully partners or out-licenses HCW9206:
$25–50M upfront payments
$150–300M in clinical and regulatory milestones
$200–400M in commercial milestones
5–10% royalties on net sales, which could generate $20–50M/year, assuming widespread integration
Total potential value: $200M to $1B+

[Frankestin]

I couldn't resist, I took a few! It's a discovery that can be sold now! It improves the costs and durability of T CAR therapies
Market Cap less than 15 M

[glenn1919]

HCWB..................https://stockcharts.com/h-sc/ui?s=HCWB&p=W&b=5&g=0&id=p86431144783

[Invest-in-America]

HCWB: But now he's totally BALD on the BACK of his head. (And the Doc also took his PUBIC HAIRS, and put them up on there, too!!)

See ME, below, right after MY recent, "FULL-SCALP-NECK-&-FACIAL-FLESH-TRANSPLANT-FROM-DONOR-HUMAN-CADAVER", procedure!!!

[Xunefox]

Lizard man

[TrendTrade2016]

tell that to matthew mcconaughy....https://www.bing.com/images/search?view=detailV2&ccid=k%2FuYWGve&id=55C2699CD1A7AEB4725012384ED482965A60778F&thid=OIP.k_uYWGverqbkOAeG96OiLAHaLJ&mediaurl=https%3A%2F%2Fwww.closerweekly.com%2Fwp-content%2Fuploads%2F2019%2F01%2FMATTHEW-MCCONAUGHEY.jpg%3Fw%3D681%26resize%3D800%252C1204&cdnurl=https%3A%2F%2Fth.bing.com%2Fth%2Fid%2FR.93fb98586bdeaea6e4380786f7a3a22c%3Frik%3Dj3dgWpaC1E44Eg%26pid%3DImgRaw%26r%3D0&exph=1204&expw=800&q=matthew+mcconaughey&simid=608026160198873220&FORM=IRPRST&ck=2249D29FE349C79A39C614707669A48A&selectedIndex=3&itb=0&cw=1186&ch=585&ajaxhist=0&ajaxserp=0

[Invest-in-America]

HCWB: That BALDNESS stuff has never, never, never, had a FIX of any frickin' type!! And hair TRANSPLANTS are plain stupid!! (This could be a 10-bagger today, IMO.)

[tw0122]

$1.02 + 263% Best of morming ...aging bald population this one a future money maker but if passes $1.20 then $1.50 next line of defense
Only have a few left was skeptical exactly on $1.20 hit so exiting now $1.04 zone before the big guys execute with gunfire lol..

[Invest-in-America]

HCWB: Monster runner!! (Bald is NOT beautiful, is trending??)

[tw0122]

Headed to $1.20 likely previous resistance before selloff

[glenn1919]

HCWB..........................https://stockcharts.com/h-sc/ui?s=HCWB&p=W&b=5&g=0&id=p86431144783

[tw0122]

.90 + 222%

[tw0122]

.80 + 190% 

[tw0122]

HCWB .70 + 153%

MIRAMAR, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, today announced that it has received clearance of its Investigational New Drug Application (“IND”) from the U.S. Food and Drug Administration (“FDA”) to initiate a first-in-human Phase 1 dose escalation clinical trial to evaluate one of its lead drug candidates, HCW9302, in patients with moderate-to-severe alopecia areata, a common autoimmune disease in humans that currently has no curative FDA approved treatments. Alopecia areata causes sudden hair loss and can have a significant negative impact on patients’ quality of life and psychological health. HCW9302 is an injectable, first-in-kind interleukin 2 (“IL-2”) fusion protein complex constructed using the Company’s proprietary TOBI platform technology. Its mechanism of action involves binding to IL-2aß? receptors predominantly expressed on regulatory T (“T_reg”) cells, thereby activating and expanding T_reg cells that can suppress unwanted immune and inflammatory responses.

Chronic inflammation is believed to be a significant contributing factor in many diseases and conditions including those that have a major impact on quality-of-life but are not life-threatening. In multiple relevant preclinical models, HCW9302 has shown efficacy in treating autoimmune diseases at well-tolerated dose levels by activating and expanding T_reg cells through subcutaneous injections. Protein-based therapies, whether as direct inhibitors or immunomodulatory agents, have revolutionized the management of autoimmune and inflammatory conditions. The Company believes that HCW9302, with its subcutaneous injectable approach, has the potential to activate and expand T_reg cells in patients, reducing inflammation, while minimizing the risk of broad immunosuppression.

Dr. Hing C. Wong, Founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative immunotherapeutic treatment of autoimmune diseases. This trial is a milestone for our Company, and the beginning of clinical development of treatments for quality-of-life indications. While not life-threatening, alopecia areata has no cure. Existing off-label treatments may provide some relief of symptoms, but there are often dangerous side effects. For those who suffer from this disease, it can negatively impact their quality-of-life.” Dr. Wong continued, “The goal of this initial trial is to establish the safe dose of HCW9302 that effectively increases T_reg cells activity in patients. Once we achieve this objective, we will rapidly expand clinical development of HCW9302 in Phase 2 studies in patients with other autoimmune diseases and inflammatory conditions, including other dermatological conditions, graft rejection, arthrosclerosis, diabetes, and neurodegenerative diseases where HCW9302 has been shown to have activity in relevant animal models.”

About Alopecia Areata:

[JPS02]

Just noticed the bid size is quite large.

[JPS02]

Looks like the pps failed to keep its levels.

[Invest-in-America]

HCWB: Hopefully, as this one is by no means totally 'over'.

[JPS02]

There has been consistent volume all day today. GARB and BTCT earlier this month had the initial first day run, the next day they pulled back and consolidated and then the third day took off. It will be interesting to see if the same happens here.

Go HCWB!

[Invest-in-America]

HCWB: Up now only 20% in the Pre-M.

[Invest-in-America]

HCWB: Will it soar AGAIN, today?????????????????????????????

[MartinLutherKing]

HCWB Live the dream RNAZ cure to cancer explosion

[SolarRevolution]

I'm in! 

[Invest-in-America]

HCWB: Whelp, unfortunately --- not to trivialize its magnificent RUN-UP earlier today --- here's its latest 'CHART', Peeps!! (See below.)

[Invest-in-America]

HCWB: Hey, THANKS, Admiral P-B!!! (Then next, I think everybody ran over to @APLM!!! Big shares FLOAT over there, though --- which SPOOKED me very early today, sending me over to this HCWB gamble.)

[powerbattles]

Congrats!

[Invest-in-America]

HCWB: Nerve-racking, Boss!!! (But had some FUN with it, & PROFITS too!!)

[Invest-in-America]

HCWB: And I leave-ya-all with the Official Wall Street THEME SONG for a stock like THIS freak show today!!!

[tw0122]

Nice one 

[Invest-in-America]

HCWB: OUT for good, but NICE one!!!! (I have to lay down for awhile.)

[Invest-in-America]

HCWB: Here's COPILOT on the matter ---

"Why is HCWB halted for so long? HCW Biologics Inc. (HCWB) stock has been halted multiple times today due to extreme volatility and high trading volume following their announcement of a worldwide exclusive license agreement with WY Biotech Co., Ltd.. The stock exchange halts trading in such situations to manage the volatility and ensure market stability. Does this help clarify the situation for you?"

[Invest-in-America]

HCWB: This may be one of those rare 15-baggers today!!!

[Invest-in-America]

HCWB: ME, Homeboy!!! (Did ya think it was somebody ELSE????)

[powerbattles]

+646.78% Who is the lucky one who bought at the bottom?